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Introduction
In fundamental cell biological processes such as signal
transduction, enzymatic activity or intracellular fusion during
vesicular transport, a large number of proteins are recruited to
and released from the cytoplasmic surface of intracellular
membranes (Casey et al., 1995; Rothman and Orci, 1992). In
order to perform their functions at the correct time and place,
some proteins must rely on regulated processes guiding their
binding to or their release from the membrane lipid bilayer
(James and Olson, 1990; Resh, 1999). In this regard,
modification with lipophilic moieties has been described as an
important mechanism involved in membrane anchoring of
cytoplasmic proteins, which tightly regulates their proper
intracellular targeting (Gonzalo and Linder, 1998; Smotrys
and Linder, 2004). Protein fatty acylation includes different
types of fatty acids, such as myristate and palmitate, or
isoprenylation with farnesyl or geranylgeranyl moieties (Zhang
and Casey, 1996; Magee and Seabra, 2003; Dietrich and
Ungermann, 2004).
Among the three human nitric oxide synthase (NOS)
isoforms that have been cloned and characterised, both NOS2
(inducible NOS) and NOS3 (endothelial NOS) are known to
become palmitoylated. In fact, the N-terminus of NOS3 is
irreversibly myristoylated at Gly2 and reversibly palmitoylated
at Cys15 and 26 in a well-known process responsible
exclusively for its targeting to caveolae (Liu et al., 1997; Feron
et al., 1998 and references therein). On the other hand, NOS2
is only modified by palmitic acid at Cys3 when both the basic
residues Lys6 and Lys10 together with the hydrophobic residue
Pro4 are present (Navarro-Lérida et al., 2004a). When the
palmitoylated Cys3 residue is substituted with Ser, the mutant
NOS2 becomes misfolded, aggregates with intracellular
membranes and does not progress along the secretory pathway.
Shortly after we described the N-terminal palmitoylation of
NOS2, the palmitoylation of the human Kv1.1 channel was
also reported (Gubitosi-Klug et al., 2005) highlighting certain
similarities in the sequences that become palmitoylated among
NOS2 (ACPWKFLFK), Kv1.1 channel (ACPSKTDFF), CD36
(ACRSKTIK) and the cation-dependent mannose-6-phosphate
receptor (VCRSKPRNV). It is tempting to speculate that,
inside the cell, these proteins and some others not yet identified
might be the substrates of the same palmitoyl transferase. This
sequence motif includes an Ala or Val residue at the –1 position
(considering the palmitoylatable Cys residue as 0), an
uncharged residue at +2 with the capacity to make hydrogen
bonds (Trp or Ser) and preferentially a Lys residue at the +3
position.
We have now addressed the mechanism by which
palmitoylation allows the proper transit of NOS2 along the
secretory pathway. In this work we have tried to gain further
We have analysed the mechanism by which palmitoylation
permits the progression of nitric oxide synthase 2 (NOS2)
along the ER-Golgi-TGN pathway. Introduction of an
additional myristoylation site at the N-terminus of NOS2
resulted in a chimera that displayed an enhanced
association with the particulate fraction and with the
plasma membrane but did not display increased enzymatic
activity. In the absence of palmitoylation, introduction of a
surrogate myristoylation site resulted in a mutant NOS2
with only 25% activity compared with the wild-type
enzyme. Hence, the novel surrogate myristoyl moiety not
only failed to increase NOS2 activity when introduced in a
wild-type sequence environment, but was also unable to
rescue the inactive phenotype of the Cys3Ser mutant.
Introduction of an additional palmitoylatable Cys at
position 2 of the wild-type sequence resulted in a chimera
that associated to a larger degree with membranes and
displayed decreased activity. Our data indicate that
palmitoylation of inducible NOS at position 3 exquisitely
determines its transit along the secretory pathway
following a route that cannot be mimicked by a surrogate
myristoylation or by a palmitate at position 2. In addition,
the exit of NOS2 from the TGN and the accumulation in
the cellular plasma membrane per se did not correlate with
increased ·NO synthesis.
Supplementary material available online at
http://jcs.biologists.org/cgi/content/full/119/8/1558/DC1
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understanding of the reasons that underlie NOS2
palmitoylation and its differences with the subcellular targeting
of NOS3 which becomes irreversibly and enzymatically
myristoylated at Gly2 and doubly palmitoylated at the side
chains of Cys15 and Cys26. This latter modification can be
modulated, hence determining the translocation of the enzyme
to caveolae/rafts and its inhibitory association with the caveolin
molecule in endothelial cells. Incubation of both recombinant
NOS2 or NOS3 with the ‘scaffolding domain’ peptide of both
caveolin-1 (residues 82-101) and caveolin-3 (residues 55-74)
completely abrogated nitric oxide synthesis (García-Cardena et
al., 1997), an observation that might suggest that within the
cell, the activity of these enzymes must be modulated through
its interaction with caveolin. However, in contrast to NOS3, the
palmitoylation of NOS2 does not result in its translocation to
caveolar domains (Navarro-Lérida et al., 2004a). Indeed,
NOS2 can become associated with caveolin-1 (and marginally
to caveolin-2 and -3) within muscle cells and this interaction
is inhibitory for the enzyme. Interestingly, in mature myotubes,
the same cytokine stimuli that induce NOS2 expression lead to
the downregulation of caveolin-1 levels, hence allowing NOS2
to reach its full activity (Navarro-Lérida et al., 2004b).
With this in mind, we have created a number of NOS2
chimeras that could allow us to inspect the functionality of
NOS2 palmitoylation. Some of our constructs result in non-
acylated, myristoylated, palmitoylated or doubly acylated
proteins. Sorting along the secretory pathway was analysed
using the drugs brefeldin A, monensin and megalomicin. Our
main conclusion is that palmitoylation of NOS2 at Cys3
determines exquisitely its correct exit from the Golgi en route
through the plasma membrane as well as its ·NO-synthesising
activity. Neither myristoylation at Gly2, nor dual palmitoylation
at Cys2 and Cys3 could substitute for palmitoylation at Cys3 in
terms of protein activation along the secretory pathway.
Apparently, each of the surrogate post-translational lipidic
modification conferred NOS2 with an erroneous subcellular
sorting route resulting in diminished enzymatic activity.
Results
Construction of NOS2 chimeras, enzymatic activity and
radiolabeling with myristic and palmitic acids
Endothelial NOS (NOS3) becomes N-terminally
myristoylated and, when subsequently palmitoylated at
positions Cys15 and Cys26 becomes targeted to caveolae (Liu
et al., 1997; Feron et al., 1998). Myristoylation is a
prerequisite for protein palmitoylation mimicking the well-
known dependence of S-acylation on prior membrane
association via myristoyl, prenyl or transmembrane peptide
moieties (Milligan et al., 1995; Dunphy and Linder, 1998;
McCabe and Berthiaume, 1999). However, we have observed
that NOS2 is palmitoylated at Cys3 without the presence of
any other lipid modification (Navarro-Lérida et al., 2004a).
With that in mind, we investigated whether a surrogate
myristoylation site in the NOS2 sequence could render a
protein with similar characteristics to endothelial NOS. First
of all, using wild-type NOS2 as template, we created different
mutants at the N-terminus of the polypeptide sequence (Fig.
1A). In the first mutant, Cys3 was changed to Ser (C3S NOS2-
GFP); the second mutant contains a myristoylation consensus
sequence at Gly2 and Ser6  (Myr-NOS2-GFP); the third is a
double mutant, containing the myristoylation site of Myr-
NOS2-GFP  together with the Cys3 to Ser mutation (Myr/C3S
NOS2-GFP); the fourth mutant combines the mutations of the
third mutant with an additional palmitoylatable Cys2 (A2C
NOS2-GFP). Since we can measure the amount of nitric oxide
released to the medium in the form of nitrites, we determined
the enzymatic products of the conversion of L-Arg into
citrulline plus ·NO by wild-type NOS2 as well as its mutant
Fig. 1. Wild-type and mutant NOS2-GFP chimeras. (A) The N-terminus of NOS2 was mutated by PCR, creating C3S, Myr, Myr/C3S and A2C
mutant chimeras fused to GFP. We created both full-length NOS2 chimeras (residues 1-1144) and short chimeras (residues 1-94). The different
NOS2-GFP constructs were inserted into a pCDNA3 vector that was used to transfect COS7 cells and the enzymatic activity (B), incorporation
of radioactive palmitate and myristate (C) and protein expression (D) were determined. Enzymatic activity of NOS2 was determined using the
Griess method as previously reported (Navarro-Lérida et al., 2004). Transfected COS7 cells were starved for 1 hour in DMEM without serum
and were then metabolically labelled for 4 hours with either [3H]myristic acid (Myr) or [3H]palmitic acid (Palm). Cell lysate proteins were












chimeras (Fig. 1B). As previously shown (Navarro-Lérida et
al., 2004a), the mutant chimera where the palmitoylatable
Cys3 was substituted with Ser practically lacked enzymatic
activity. Introduction of a myristoyl tag at the N-terminus
rendered a mutant protein with very similar activity rate when
compared with the wild-type phenotype. Remarkably, in the
absence of palmitoylation, myristoylation alone (Myr/C3S
chimera) was unable to match the wild-type proteins in terms
of catalysis, displaying ~27% of wild-type NO-synthesising
activity. Somewhat surprisingly, two consecutive
palmitoylatable Cys residues also produced a chimera with
reduced activity, displaying 50% activity when compared with
the wild-type protein (Fig. 1B).
To inspect the targeting signals contained within the N-
terminus per se, every construct was obtained as a full-length
NOS2-GFP chimera and as a NOS2 (1-94 amino acid) GFP
chimera, the latter lacking the caveolin-1-interacting motif.
Metabolic radiolabelling of the full-length and (1-94)-GFP
constructs was performed using [9,10-3H]-myristic acid or
[9,10-3H]-palmitic acid followed by immunoprecipitation of
the cell lysates with the anti-GFP antibody (Fig. 1C). Only
GFP chimeras that possessed the N-terminal Gly in the context
of a consensus myristoylation sequence (Ser6) incorporated
myristic acid (Myr, and Myr/C3-GFP) resulting in the efficient
incorporation of palmitic acid in the wild-type NOS2 and Myr
NOS2-GFP constructs. Remarkably, the myristoylated and
palmitoylated mutant showed a higher level of incorporation
of palmitate than its wild-type NOS2 counterpart. As expected,
transient transfection of COS7 cells with the different pCDNA
plasmids containing the chimeric GFP cDNAs resulted in
similar levels of expression for all the recombinant proteins
(Fig. 1D). The doublet observed in the case of the 1-94 GFP
chimeras is indicative of a certain degree of proteolysis
observed for these constructs (see below).
Immunofluorescence of the NOS2 chimeras and
colocalisation with the Golgi apparatus marker -cop
To examine the subcellular expression patterns of each mutant,
plasmids encoding GFP-tagged wild-type NOS2, C3S NOS2,
Myr NOS2 and Myr/C3S NOS2 were transfected in COS7 cells
and examined by confocal microscopy (Fig. 2).
Immunofluorescence data indicated that all the full-length
chimeras were excluded from the cell nucleus and associated with
perinuclear or plasma membrane areas to a different extent.
Interestingly, introduction of a surrogate myristoylation site
produced a mutant protein that associated with the plasma
membrane to a greater degree when compared with the wild-type
NOS2 distribution (Fig. 2A). Probably this plasma membrane
enrichment of the myristoylated and palmitoylated mutant is
related to the difference in the level of incorporation of palmitate
shown between the Myr NOS2 mutant and the wild-type NOS2
because some palmitoyltransferase activities are known to
become enriched in the plasma membrane (Dunphy et al., 1996;
Bijlmakers and Marsh, 2003). Mutation of the Cys3 to Ser in
NOS2 created a recombinant chimera that accumulated to cis-
Golgi areas (Navarro-Lérida et al., 2004a). However, introduction
of a novel myristoyl moiety (Myr/C3S mutant) was unable to
recover the phenotype of the wild-type NOS2, although it
conferred important changes on C3S NOS2 distribution. In fact,
the myristoylated and non-palmitoylated chimera changed the
cis-Golgi accumulation into a multiple intracellular membrane
Journal of Cell Science 119 (8)
localisation, (including the nuclear envelope) and an enrichment
in perinuclear areas showing a partially cytoplasmic distribution
in the cell. However, in the absence of palmitoylation, no plasma
membrane staining could be observed.
To elucidate the role of the N-terminal end in the absence of
interference from the caveolin-binding motif (FPAPFNGW)
that is found spanning residues 358-366, we created deletional
chimeras of NOS2-GFP containing only the first 94 amino acids
of NOS2 fused to GFP (Fig. 2B). These constructs would
presumably localise to certain subcellular regions dictated only
by the acylation state of the N-terminus. Unlike the full-length
chimeras, the wild-type and the C3S NOS2(1-94) chimeras
displayed partial nuclear staining. On the other hand, the
myristoylated and palmitoylated mutant Myr NOS2(1-94) and
the mutant exclusively modified by myristic acid were excluded
from the nucleus (Fig. 2B). The presence of both lipid moieties
confers to the Myr NOS2(1-94) mutant a practically exclusive
plasma membrane localisation and a focal perinuclear staining.
This phenotype contrasts with the subcellular distribution of the
Myr/C3S mutant where the elimination of the putative
palmitoylation site Cys3 introducing a myristoylation site
results in a distribution characterised by the nuclear exclusion
and the completely loss of plasma membrane staining, with an
enrichment in intracellular membrane as well as in the ER. This
clearly resembles the phenotype shown by the Myr NOS2
mutant when treated with 2-Br-palmitate (Fig. 2C). Since we
wanted to determine whether the perinuclear staining of the
NOS2(1-94) chimeras corresponded with Golgi network
labelling, double immunofluorescence was performed with the
Golgi marker -cop (Fig. 2D). We compared the subcellular
distribution of a myristoylated plus palmitoylated (Myr), a
myristoylated (Myr/C3S) and a doubly palmitoylated (A2C)
NOS2(1-94) chimera with myristoylated plus palmitoylated
endothelial NOS chimeras known to be enriched in rafts
(Navarro-Lérida et al., 2002). In all four cases the staining
observed in perinuclear areas corresponded to the Golgi
network, as indicated by the -cop colocalisation. However, the
subcellular distribution was different in all cases. Whereas the
Myr/C3S chimera displayed a distribution that indicated that
upon exiting the Golgi it associated with other intracellular
vesicles, both the dually palmitoylated A2C and the dually
acylated Myr NOS2(1-94) chimeras showed clear Golgi and
plasma membrane staining with no traces of label in TGN or
intracellular vesicles. The dual Golgi-plasma membrane
immunofluorescence is especially apparent in the case of the
Myr NOS(1-94) chimera. However, NOS3, which becomes
myristoylated and palmitoylated does localise to the Golgi,
TGN and partially in the plasma membrane (Fig. 2D, bottom
row).
Membrane partitioning, enrichment in DRMs and
colocalisation with caveolin-1
To investigate the effect of the various acylation states on the
membrane partitioning of the full length or (1-94) GFP
chimeras, we fractionated cellular lysates containing identical
amounts of each chimera into supernatant (S-soluble)
and pellet (P-membrane associated) fractions after
ultracentrifugation at 200,000 g (Fig. 3A). The palmitoylated
wild-type full length NOS2 transfected in COS7 was found
both in the soluble and particulate fractions (in an approximate
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Myr-NOS2 GFP or a mutant of NOS2 where an additional
palmitoylatable Cys residue was introduced at position 2
(dually palmitoylated mutant A2C NOS2-GFP) were
associated with the membrane fraction to >80%. Myristoylated
but not palmitoylated (Myr/C3S-GFP) was found distributed in
both fractions, but the majority (at least ~60% on average) was
found in the soluble fraction (Fig. 3A). In this case, N-terminal
myristoylation increased the overall hydrophobicity of the
engineered GFP chimeras resulting in an increased association
with cellular membranes, specially in the case of the Myr
NOS2-GFP mutant where the dual acylation leads to a
practically 100% of fractionation into pellet. In the case of the
short chimeras, introduction of any additional acyl chain also
resulted in increased association with the particulate fraction
of the cells (Fig. 3A, right plot).
We next analysed the targeting of the various acylated
constructs of NOS2 to the Triton-X100-insoluble membranes
(DRMs) preparing 40:30:5% sucrose discontinuous gradients
in the presence of the detergent following a well-defined
procedure of caveolae extraction (Lisanti et al., 1999). The
majority of both the full-length and (1-94) wild-type NOS2
appeared in the high-density fractions (at the bottom of the
tube) and a very limited amount of protein co-fractionated with
DRMs (Fig. 3A). In fact, association with DRMs resulted in
proteolytic degradation by the proteasome (Felley-Bosco et al.,
2000; Navarro-Lérida et al., 2004b). In contrast to the expected
results, only a very limited amount of the full-length and (1-
94) Myr NOS2 chimeras were observed in DRMs: this was
most of the immunodetected protein associated with the Triton
X-100-soluble fractions at the bottom of the tube. These data
contrast with the distribution of the short Myr NOS2-GFP and,
to a lesser extent, the full-length construct in the plasma
membrane. In the absence of palmitoylation, myristoylation
alone seemed to be unable to target either the full-length or the
(1-94) Myr/C3S NOS2 chimeras to DRMs. Nevertheless, dual
palmitoylation resulted in a significant enrichment of A2C
NOS2 in DRMs, both in the full-length construct and its short
counterpart. In any case, translocation to DRMs detected in our
positive control of caveolar targeting linker-(SAG)9-GFP
(Navarro-Lérida et al., 2002) was not attained by any of the
Fig. 2. Subcellular localisation
of the various constructs and
laser confocal microscopy with
the Golgi marker -cop. COS7
cells were transfected with the
various NOS2-GFP constructs
and the fluorescence was
analysed 36 hours post
transfection. The subcellular
localisation of the full-length
NOS2-GFP chimeras (A) and the
(1-94)-NOS2 chimeras (B) was
determined. Changes induced in
the subcellular distribution of the
Myr chimera when treated with
10 M 2-Br-Palmitate were also
determined (C). In order to
determine the colocalisation of
the Myr, Myr/C3S and A2C
NOS2(1-94) chimeras with the
Golgi marker -cop, double
immunofluorescence staining
was performed using a Cy3-
conjugated secondary antibody.
As a positive control, we used
residues 1-55 of NOS3 fused to
GFP, which is known to become
myristoylated and palmitoylated
(Navarro-Lérida et al., 2002).
Cell nuclei were stained with













NOS2 constructs. When we tried to correlate the flotation
experiments with the double staining with caveolin-1
antibodies we concluded that the plasma membrane
immunolocalisation displayed by caveolin-1 in COS7 cells
stained areas that were also positive for three of our chimeras:
Myr, Myr(1-94) and A2C (1-94) (Fig. 3B). We determined that
Journal of Cell Science 119 (8)
10% of the Myr full-length GFP fluorescence colocalised with
caveolin-1, 32% in the case of the Myr(1-94) chimera and 11%
in the case of the A2C chimera. In consequence, the
colocalisation of our NOS2-GFP chimeras with caveolin-1 in
the plasma membrane does not fully correlate with DRM
enrichment detected by Triton X-100 sucrose gradients. This
Fig. 3. Subcellular fractionation of COS7 cells expressing the various GFP constructs. (A) Transfected COS7 were lysed and after clarification
of the cellular debris by centrifugation, fractionated into supernatant (S) and pellet (P) fractions by ultracentrifugation for 16 hours at 200,000 g
as described in the Materials and Methods section. The fractions were subjected to a SDS-PAGE, analysed by western blot with an antibody
against GFP and the resulting bands were quantified using UVIband V97 software. In addition, COS7 cells transfected with the tagged GFP
constructs were extracted in the presence of Triton X-100 at 4°C and subjected to centrifugation on a 40:30:5% sucrose gradient. After
centrifugation, the gradient tubes were divided into 12 equal aliquots collected from the bottom and analysed by SDS-PAGE and western blot
(lower panels). (B) COS7 cells were transfected with the Myr, Myr (1-94) and A2C (1-94) NOS2-GFP. The bottom right panels are the merges











1563Palmitoylation induces NOS2 transport
led us to conclude that plasma membrane immunofluorescence
did not necessarily correspond with caveolae enrichment,
despite the coincidence with caveolin-1 labeling.
Different kinetics of wild-type, Myr and A2C NOS2(1-94)
distribution in COS7 cells
At this point we evaluated the intrinsic differences conferred
by either a palmitoyl or a myristoyl moiety located at the N-
terminus of NOS2 in terms of transit along the secretory route.
Modulation of different exocytic steps at a low temperature
(25°C) corroborated the fact that wild-type NOS2 and Myr
NOS2-GFP followed distinct routes towards the plasma
membrane. Since the fusion of the cis-, medial- and trans-Golgi
cisternae necessary for protein sorting is a temperature-
dependent process, a further experiment was performed in
which 8 hours after transfection at 37°C, the COS7 cells were
transferred into a CO2 incubator maintained at 25°C. Under
conditions where identical amounts of protein were considered,
the wild-type NOS2 was approximately 44% active when
temperature of the cells had been lowered down to 25°C and
the GFP fluorescence accumulated appreciably in areas
adjacent to the cell nucleus (Fig. 4A). Both at 37°C and 25°C
the mutant C3S NOS2 chimera displayed very low activity,
concomitant with a clear perinuclear fluorescence. Finally, the
myristoylated and palmitoylated mutant expressed at 25°C
showed only a 20% decrease in its ·NO synthesising activity
when compared with the rates at 37°C, with no significant
changes in its cellular distribution (Fig. 4A, right panel). It is
Fig. 4. Nitric oxide synthesis, subcellular
targeting of the NOS2 chimeras at 25°C
and in vivo recovery of the subcellular
localisation of the wild-type and Myr
NOS2 chimeras. (A) COS7 cells were
transfected with the wild-type, Myr and
C3S NOS2 chimeras and the cells were
grown at both 37°C and 25°C. The NOS2
activity was determined at both
temperatures using the Griess assay and
was represented relative to the wild-type
(relative units, RU) at 37°C (usually about
20 M nitrites). At the same time, the
cells grown at 25°C were fixed and
analysed by laser confocal microscopy
following the GFP fluorescence after
excitation at 488 nm. (B) Areas in the
plasma membrane with positive
fluorescence for GFP (boxed) were
selected in the wild-type, Myr (1-94) and
A2C(1-94) NOS2 chimeras. The green
fluorescence was bleached with the laser
and the cell was allowed to recover the
plasma membrane fluorescence for 30
minutes. The recovery is representative of
three independent experiments. The ratio












particularly noticeable that the Myr NOS2 chimera could still
display plasma membrane immunofluorescence even in cells
grown at 25°C.
Fig. 4B shows the fluorescence recovery in the plasma
membrane of wild-type NOS2(1-94), Myr NOS2(1-94) and
A2C NOS2(1-94) after photobleaching with the laser beam.
For photobleach experiments, an area of plasma membrane
GFP was bleached using the 488 nm laser line and the recovery
was monitored scanning once every 30 seconds for 30 minutes.
The velocity of recovery of the plasma membrane staining was
three to four times faster in the case of the myristoylated and
A2C singly palmitoylated mutant compared with the wild-type
NOS2, suggesting that the secretory pathways followed by the
double acylated mutants (either myr-palm or palm-palm) are
different from the wild-type NOS2 (Fig. 4B). In fact, after 10
minutes, only a very limited recovery was observed in the case
of the wild type chimera (Fig. 4B bottom plot). Although
we cannot rule out the possibility of a redistribution of
fluorescently-tagged chimeras from other areas of the cell, our
data suggest that myristoylation and double palmitoylation, in
addition to contributing to the targeting of NOS2 to the plasma
membrane, increases the speed of movement of NOS2 from
the ER through the Golgi pool towards the plasma membrane.
Effect of nitric oxide on NOS2 progression along
intracellular pathways
Nitric oxide is known to prevent addition of the palmitate
moiety to certain neuronal proteins such as GAP43 and SNAP-
25 hence restricting neuronal growth (Hess et al., 1993). Since,
in theory, NOS2 could be responsible self-catalytically for the
attachment-detachment of the palmitoyl moiety to its Cys3
residue we analysed the sites of intracellular synthesis of ·NO
using the probe DAR, known to react with nitric oxide
rendering a fluorescent precipitate that does not diffuse
significantly (Fig. 5). At this point, it was conceivable that only
the plasma-membrane-localised NOS2 might be active
whereas the pool associated with the ER and Golgi apparatus
lacks activity. Unexpectedly, all the intracellular NOS2 proved
Journal of Cell Science 119 (8)
to possess ·NO-synthesising activity, as demonstrated by the
DAR reactivity, that was practically coincident with the NOS2
immunofluorescence. A pixel-by-pixel analysis revealed that
92.8% of the DAR red fluorescence colocalised with the
NOS2-GFP fluorescence. As expected, NOS2-negative cells
displayed no synthesis of nitric oxide (Fig. 5A). Once we
proved that the inducible nitric oxide was active in the cytosol
of the cells we intended to ascertain if the availability of
either the NOS2 substrate L-Arginine or the cofactor
tetrahydrobiopterin were limiting its enzymatic activity, hence
promoting the progression of NOS2 along the secretory
pathway. Therefore, to examine the importance of the correct
transit through the ER-Golgi trans-Golgi compartments to
reach full activity of NOS2 en route to the plasma membrane,
activity changes of wild-type NOS2, C3S or Myr NOS2
mutants were analysed after addition of extra L-Arginine (10
mM) and tetrahydrobiopterin (10 M) to the medium (Fig.
5B). Curiously, the presence of both compounds in the medium
concomitantly produced only a moderate increase in the
activity of wild-type and Myr NOS2, whereas C3S NOS2 was
not affected. This suggests that active NOS2, upon its exit from
the Golgi apparatus reaches full activity when larger amounts
of the cofactor tetrahydrobiopterin and the substrate L-arginine
become available. In addition, the inability of the C3S mutant
to synthesise nitric oxide must be due to its lack of
palmitoylation, which could result in the inability to dimerise
or in an incorrect transit, rather than the deficiency in substrate
or cofactor. On the other hand, the addition of the NOS2
inhibitor 1400W or the ·NO donor DetaNONOate to the wild-
type NOS2 did not alter its subcellular distribution: a fact that
indicates that nitric oxide itself does not determine the
intracellular transit of inducible nitric oxide synthase (Fig. 5C).
Both in the absence of ·NO synthesis (with 1400W) or with
excess ·NO, NOS2 was still able to partially reach the plasma
membrane (see arrows in Fig. 5C). This suggests that the
NOS2-generated nitric oxide is not responsible for reacting
with the free thiol in the side chain of Cys3, hence inhibiting
palmitoylation of its own N-terminus.
Fig. 5. Localisation of the sites of intracellular synthesis
of ·NO in vivo, NOS2 activity in the presence of
additional substrate and cofactor and effect of the NOS2
inhibitor 1400W and the ·NOS donor DETA-NONOate
on the NOS2 fluorescence. (A) COS7 cells were
transfected with the full-length wild-type NOS2-GFP and
36 hours post-transfection, the cells were incubated in
vivo with 5 M of the ·NO-sensitive probe diamino-
Rhodamine-4M (DAR-4M) for 1 hour at 37°C. The
location of the intracellular sites of ·NO synthesis is
indicated in red. (B) COS7 cells transfected with the
wild-type, C3S and Myr full-length NOS2-GFP chimeras
were incubated with (shaded bars) or without (black bars)
an excess of the NOS2 substrate L-Arg (10 mM) and the
cofactor H4B (10 M) and ·NO-synthesising activity was
determined. (C) Changes in the immunofluorescence
signal of the wild-type full length NOS2-GFP chimera
after addition of 100 M of the NOS inhibitor 1400W or
100 M of the ·NO donor DETA-NONOate. Arrows
indicate the plasma membrane areas where the NOS2
GFP fluorescence can be observed. Cell nuclei were
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Disruption of the secretory pathway by brefeldin A
abrogates NOS2 palmitoylation
Maturation of newly synthesised NOS2 into the palmitoylated
form requires the association of the soluble protein with a
palmitoyl transferase. Because palmitoylation of proteins can
occur during transit through the secretory pathway or at the
plasma membrane (Bijlmakers and Marsh, 2003) we tested
whether disruption of the secretory pathway in the different
steps of the route towards the plasma membrane affected
palmitoylation of wild-type NOS2. Brefeldin A treatment,
which inactivates Arf 1, is known to lead to the dissociation of
COP I and other peripheral proteins from the Golgi membrane,
resulting in Golgi enzymes redistributing to the ER as the Golgi
structure disassembles (Klausner et al., 1992). On the other
hand, the ionophore monensin is commonly used to partially
disrupt the integrity of the Golgi network and to inhibit
vesicular transport in eukaryotic cells (Griffiths et al., 1983).
Finally, megalomicin produces profound morphological and
functional alterations on the Golgi complex of cultured cells
causing an enlargement of lysosomes and inhibiting functional
delivery of proteins in the TGN (Bonay et al., 1996). Wild-type
NOS2-GFP-transfected COS7 cells were treated with
increasing concentrations of brefeldin A, monensin or
megalomicin. Both brefeldin A and monensin drastically
diminished the ·NO synthesis to 29 and 43% of the levels in
the control at 10 M respectively, whereas the addition of
megalomicin produced only a small effect on NOS2 activity,
which diminished to 70% of the control level (Fig. 6A).
Curiously when we correlated these results with the
incorporation of palmitic acid, BFA significantly inhibited the
incorporation of [3H]palmitate into NOS2 whereas the other
two agents produced a limited effect on NOS2 palmitoylation.
We also tested the effect of BFA on the myristoylated and
palmitoylated NOS2 mutant. The data show that the
palmitoylation of this mutant was insensitive to BFA (Fig. 6B).
These results are consistent with the results obtained in the case
of the doubly acylated p59fyn in which palmitoylation is not
affected by treatment with BFA (van’t Hof and Resh, 1997). In
consequence, drugs that affect the Golgi integrity, as well as
the ER-to-Golgi transit or the Golgi-TGN progress, affect
NOS2 activity. However, only BFA, when maintained
throughout the entire radiolabeling process, drastically
diminished palmitoylation of NOS2, rendering the most
profound reduction in ·NO-synthesising activity.
The first 33 amino acids of NOS2 are not part of the
catalytic core of the enzyme
Next, we wondered if the N-terminus of NOS2 might be
involved in catalysis and if the changes detected in our mutant
chimeras might arise from alterations in the three-dimensional
folding of the protein. In addition, we also wanted to
demonstrate whether, as in the case of NOS1 and NOS3, the
N-terminus of NOS2 is involved in subcellular targeting.
Hence, we created a deletion mutant of the first 33 amino acids
of the recombinant NOS2 and expressed it in E. coli, a
recombinant system with a simple post-translational
mechanisms where we might bypass all the complex sorting
machinery that mammalian cells possess. An additional
advantage of E. coli as recombinant expression system for
NOS is that the protein is inactive within the cell, because the
bacteria lack tetrahydrobiopterin and calmodulin (Rodríguez-
Crespo et al., 1996a). Very pure protein was obtained after
purification by sequential affinity chromatography, first
through the binding to a Ni2+-NTA resin by means of the N-
terminal polyHis tag and subsequently by binding to 2,5-
ADP-Sepharose column through the C-terminal NADPH
binding site (Fig. 7A). The absorbance spectrum was
characterised by a high-spin peak at 394 nm in the presence of
L-Arg and H4B and flavin absorption maxima at ~460 and 485
nm; these are indistinguishable from that of the wild-type
protein (Nishida and Ortiz de Montellano, 1998). In addition,
whereas the boiled sample gave a clear monomeric (M) band
with Coomassie Blue, a small amount of dimers (D) and
monomers could be seen in the lane of the unboiled sample
Fig. 6. Agents that disrupt the ER-to-Golgi traffic affect NOS2
activity and subcellular distribution. COS7 cells were transfected
with the full-length wild-type (A) and Myr (B) NOS2-GFP chimeras
and 12 hours later increasing concentrations of brefeldin, monensin
or megalomicin were added to the cell culture for 16 hours. After the
treatment, the NOS2 activity was determined with the Griess assay.
In a parallel experiment, COS7 cells transfected with their (1-94)
counterparts were incubated with or without the desired drug for 4
hours, then starved for 1 hour in DMEM without serum and were
then metabolically labelled for 4 hours with [3H]palmitic acid.
Brefeldin A, monensin, megalomicin or DMSO (control) levels were
maintained during the labelling period. The incorporation of
radiolabelled palmitate was assessed both for wild-type NOS2(1-94)-
GFP (A, bottom panel) and Myr NOS2(1-94) (B, left-hand panel,













(Fig. 7A, insert). The presence of SDS-resistant dimers reflects
the effective dimerisation of the sample in solution (Klatt et al.,
1995). Although this mutant lacks the palmitoylation site and
the neighbouring basic or hydrophobic amino acids (Pro 4 or
Lys 6 and 10), it retains full catalytic activity compared with
the recombinant NOS2 wild type (Fig. 7B). This result clearly
establishes that the N-terminus of NOS2 (the first 33 amino
acids) is dispensable for catalytic activity and is required for
subcellular localisation when induced by cytokines or when
transfected in mammalian cells.
Subcellular distribution of cytokine-induced NOS2
compared with the palmitoylated proteins PSD-95 and
GAP-43
PSD-95 and GAP-43 are two well-characterised N-terminally
palmitoylated proteins. Since treatment with cytokines induces
the expression of NOS2 in multiple cell types we compared the
subcellular distribution of endogenous NOS2 with transfected
GAP-43 and PSD-95. When we transfected N-terminally
palmitoylated wild-type PSD-95 and GAP-43 in COS7 cells
we could observe immunofluorescence phenotypes that
differed from that observed for the wild-type NOS2-GFP
chimera (Fig. 8A). PSD-95-GFP displays a clear pattern of
nuclear staining, a diffuse immunofluorescence along the cell
cytoplasm and clear plasma membrane staining, whereas GAP-
43 is absent from the cell nucleus, and distributes in patches in
the cytoplasm in addition to the plasma membrane. In neither
case could we observe the large perinuclear staining
characteristic of Golgi network localisation that is observed in
the case of wild-type NOS2-GFP. We can therefore conclude
that the three N-terminally palmitoylated proteins differ in their
subcellular distribution. In order to shed some light into the
different staining patterns displayed by PSD-95 and NOS2
we transfected PSD-95-GFP in two cell lines in which
inflammation can be induced with a mixture of cytokines and
bacterial lipopolysaccharide, such as mouse C2C12 myotubes
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Fig. 7. Residues 1-33 of NOS2 are not part of the catalytic core of
NOS2. (A) Absorbance spectrum of the recombinant NOS2 (33)
expressed in E. coli. The contribution of the heme prosthetic group is
centered around 390 nm whereas the contribution of the FAD and
FMN flavins is centered around 450 nm. The insert shows a
Coomassie Blue-stained gel with molecular weight markers (M),
boiled (B) NOS2 and unboiled (U) NOS2, where the SDS-resistant
dimers (D) can be partially observed as distinct form the monomers
(M). Approximately 2 g of purified protein were loaded per lane.
Panel B show the catalytic activity of the recombinant NOS2(33)
(delta-33) protein compared with the wild-type NOS2 (wt).
Fig. 8. The subcellular distribution of the palmitoylated proteins PSD-
95, GAP-43 and NOS2 is different in COS7 cells, C2C12 myotubes
and H9C2 cardiac myocytes. (A) Both PSD-95-GFP and GAP-43-
GFP constructs were transfected in COS7 cells and the subcellular
distribution was analysed with the Golgi marker -cop labelled with a
Cy3 secondary antibody (red). The right panels show the merges of
the three fluorescence signals. Cell nuclei were stained with Hoechst
33258 (blue). (B) Mouse C2C12 myoblasts were converted into
myotubes and a PSD-95 construct was transfected in the presence of a
mixture of the cytokines LPS and IFN- that induce NOS2
expression. Inducible NOS is present to differing degrees in most of
the cells with a patchy distribution (red staining). A magnified image
of the boxed area in the merged image shows the colocalisation more
clearly (right panel). (C) H9C2 rat cardiac myocytes were transfected
with a PSD-95 construct in the presence of a mixture of the cytokines
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and H9C2 cardiac myocytes. C2C12 myoblasts were converted
into C2C12 myotubes and induction of NOS2 was achieved
with a mixture of LPS and IFN- (Navarro-Lérida et al.,
2004b) (Fig. 8B). When we transfected these myotubes with
PSD-95-GFP, and compared their subcellular distribution with
NOS2 stained with Cy3 (red), we could observe through laser
confocal microscopy that most of the cells in the culture
induced NOS2 expression which in turn displayed more
particulate association with intracellular membranes and
associated with perinuclear regions of the cell. Conversely,
PSD-95-GFP could reach the plasma membrane and showed a
more diffuse distribution along the cytoplasm (Fig. 8B, insert).
Although there are certain areas of colocalisation, NOS2
displayed a patchy distribution that was not observed with
PSD-95. Even larger differences were observed when NOS2
was induced in cardiac H9C2 myocytes and PSD-95-GFP was
transfected (Fig. 8C). Most of the cells in culture expressed
NOS2 (red Cy3 staining) that distributed in perinuclear
secretory vesicles that irradiate from the nucleus. On the other
hand, PSD-95-GFP stained the nucleus, the plasma membrane
and distributed in fibre-like structures along the cytoplasm. In
conclusion, the information conferred by the N-terminal
palmitoylation of NOS2, PSD-95 and GAP-43 is not sufficient
to dictate a similar pattern of distribution in subcellular
compartments.
The non-palmitoylated C3S chimera is able to form
dimers with the palmitoylated wild-type NOS2
Since our non-palmitoylated full-length C3S NOS2 chimera
does not show enzymatic activity, we next investigated if
palmitoylation of NOS2 mediates its ability to form dimers
inside the cell. Using a commercial antibody that recognises
the C-terminus of NOS2 together with an antibody that
recognises GFP we could determine whether the (1-94)-GFP
chimeras of the wild-type NOS2 and its C3S mutant can
associate with the full-length NOS2 that is not tagged with
GFP. When we used an anti-NOS2 antibody to
immunoprecipitate the full-length NOS2 in association with
the short chimeras cotransfected in the same cell we could
precipitate both the wild-type protein as well as its non-
palmitoylated counterpart (Fig. 9A, upper panel). When
we performed the opposite experiment, that is
immunoprecipitation of the GFP-tagged short chimeras with
anti-GFP antibodies in cells cotransfected with non-tagged
NOS2, we could retrieve the full-length wild-type NOS2 in
association with the first 94 residues of both the wild-type
NOS2 and the C3S mutant (Fig. 9, bottom panel). We could,
therefore, conclude that the absence of activity of the C3S
mutant is not due to its impaired dimerisation ability but rather
to a defect in the subcellular traffic.
Discussion
The 3D structures of the heme domains of all three NOS have
been obtained using recombinant protein preparations where
the N-termini have been removed. In addition to facilitating
crystallisation, it was assumed that these N-terminal extensions
were involved in intracellular targeting of the enzymes. For
instance, deletion of as many as 226 amino acids from the N-
terminus of NOS1 produced a recombinant protein that
maintained enzymatic activity at similar levels to its wild-type
counterpart (Brenman et al., 1995). These first 226 residues
contain a PDZ domain known to bind to numerous multi-PDZ
proteins present at the post-synaptic region in neurons as well
as to skeletal muscle syntrophin (Brenman et al., 1996). In the
case of NOS3, there is abundant literature that establishes
how the protein becomes N-terminally myristoylated and
palmitoylated at Cys15 and Cys26 in a process required for
caveolae targeting (Liu et al., 1996; Feron et al., 1998 and
references therein). Somewhat unexpectedly, deletion of the
first 52 residues of NOS3 renders a recombinant protein that
retains the ability to form dimers as well as complete
enzymatic activity (Rodríguez-Crespo et al., 1997). To the best
of our knowledge, no N-terminal deletion studies have been
performed on full-length NOS2, although as in the case of
NOS1 and NOS3, the N-terminal end of the protein is probably
involved in subcellular targeting. In fact, the crystal structure
of the heme domain of NOS2 has been obtained after the
deletion of 65 amino acids (Crane et al., 1998).
We have recently shown that after synthesis, NOS2 becomes
palmitoylated at Cys3 and travels along the exocytic sorting
route, partially reaching the plasma membrane (Navarro-
Lérida et al., 2004a). With this in mind, we have created NOS2
chimeras fused to GFP and studied the mechanisms by which
NOS2 progresses along the exocytic pathways. We have
used complimentary techniques to demonstrate that: (1)
palmitoylation of NOS2 determines its Golgi exit and its
enzymatic activity; (2) myristoylation plus palmitoylation
Fig. 9. The non-palmitoylated C3S is able to form dimers. COS7
cells were cotransfected with full-length NOS2 with either the wild-
type or the C3S (1-94)-NOS2-GFP chimera. Antibodies that
recognise the C-terminus of NOS2 or the GFP tag were used
independently to immunoprecipitate the complexes. The
immunodetection (western blot) was performed using both anti-GFP
antibodies (upper panel) and anti-NOS2 antibodies (bottom panel).
The (1-94) NOS2-GFP chimeras appear at 42 kDa whereas the












leads to a chimera without increased enzymatic activity that
reaches the plasma membrane within minutes in a process
that is independent of the temperature; (3) a surrogate
myristoylation site is unable to substitute for palmitoylation;
(4) introduction of an additional palmitoylation site at Cys2
leads to caveolae targeting and probably to proteasomal
degradation; (5) the N-terminus of NOS2 is not part of the
catalytic part of the enzyme but rather an amino acid stretch
where palmitoylation occurs as a mechanism of control of ·NO
synthesis in vivo; (6) the amino acid sequence of NOS2, in
conjunction with the N-terminal palmitoylation at Cys3
determines the subcellular localisation of the protein.
Since monomeric NOS2 is known to be inactive, our results
indicate that after synthesis, NOS2 dimerises, palmitoylation
allows the exit from the Golgi and the protein becomes active
before reaching the plasma membrane. Our data suggest that
the inactive, non-palmitoylated C3S mutant is able to form
dimers although it becomes aggregated in the Golgi complex.
Consequently, we found no clear correlation between
palmitoylation and dimerisation, unlike the case of PSD-95
(Hsueh et al., 1997). In fact, when recombinantly expressed in
E. coli, wild-type NOS2 is purified in its non-palmitoylated
state (the bacteria lack palmitoyl transferase machinery) being
active and dimeric (Nishida and Ortiz de Montellano, 1998).
By analogy with the neuronal proteins SNAP25 and GAP-
43 (Gonzalo and Linder, 1998; Bijlmakers and Marsh, 2003),
palmitoylation of NOS2 can be blocked by treatment with
brefeldin A, but not by monensin or megalomicin. These two
proteins are known to be located at axons but first accumulate
at the TGN and are then transported bound to vesicles towards
the plasma membrane. Hence, palmitoylation of NOS2
requires functional Golgi membranes either to be delivered to
a specific location or, perhaps, to facilitate the palmitoylation
reaction itself (Fig. 6). By contrast, both monensin and
megalomicin also affect NOS2-mediated ·NO synthesis, albeit
to a different extent to brefeldin A. Thus, alterations in the
sorting route of NOS2 in the Golgi-TGN machinery also have
implications for activity. Our observation that brefeldin A is
unable to abrogate palmitoylation of the Myr mutant clearly
reinforces the idea that myristoylation conveys an alternative
route of sorting on wild-type NOS2, which differs from that
followed by the wild-type polypeptide.
In the case of endothelial NOS3, the purified recombinant
nonpalmitoylated mutant is catalytically indistinguishable
from the wild-type enzyme, but produces less ·NO in
stimulated cells (Liu et al., 1996). Likewise, we have created
a deletional NOS2 in which we have removed the
palmitoylatable Cys as well as the neighbouring residues.
When expressed in E. coli, this enzyme synthesises ·NO at
similar levels than the wild-type recombinant protein. Hence,
as in the case of NOS1 and NOS3, we have demonstrated here
that the N-terminus is not part of the catalytical core of the
enzyme. The absence of activity observed in the case of the
C3S mutant, together with its increased proteolysis (Navarro-
Lérida et al., 2004a) must correlate with the cellular quality
control machinery, which recognises the inability of this
construct to progress along the sorting pathway and probably
targets it for degradation.
We also observed clear differences in the subcellular
distribution of NOS2 when compared with GAP-43 and PSD-
95, two other N-terminally palmitoylated polypeptides (Fig. 8).
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We correlate these differences with the dissimilar amino acid
sequences of these proteins as well as with the interaction with
other cellular proteins. In fact, our wild-type NOS2 is not
enriched in caveolae and even the non-palmitoylated C3S-C5S
double mutant of PSD-95 can be targeted to rafts/caveolae
(Perez and Bredt, 1998). Considering that NOS2 is synthesised
in multiple cell types that are polarised (i.e. hepatocytes,
epithelial cells, neurons) it is conceivable that palmitoylation
of NOS2 also acts as a targeting signal for vectorial ·NO
synthesis in certain tissues. Similarly, palmitoylation of PSD-
95 together with a specific N-terminal amino acid sequence
mediates its traffic with vesiculotubular structures to dendritic
clusters in hippocampal neurons but also to the basolateral
membrane of polarised epithelial cells (El-Husseini et al.,
2000; Christopherson et al., 2003). In this particular case, the
PDZ domains of PSD-95 determines the subcellular
positioning of the protein together with the signals conveyed
by the palmitoylation motif, both of them being indispensable
for the correct targeting of PSD-95. We suspect that a similar
situation is occurring in the case of NOS2, in which the
concerted action of palmitoylated plus certain protein-protein
interactions dictates the subcellular localisation. At this point
we must comment on the fact that 70 N-terminal amino acids
of NOS2 are known to interact with the membrane protein
NAP110 (a protein of unknown function) as well as with
kalirin (Ratovitski et al., 1999a; Ratovitski et al., 1999b). Since
it is not established how NOS2 interacts with these two
polypeptides during its sorting as well as the functional
significance of these interactions, it remains to be confirmed
how palmitoylation would affect binding to these two proteins.
It is then plausible that palmitoylation enables the interaction
of NOS2 with either kalirin or NAP-110.
Materials and Methods
Materials
The source of most of the materials has been described before (Navarro-Lérida et
al., 2004a; Navarro-Lérida et al., 2004b). L-Arginine and tetrahydrobiopterin were
obtained from Merck. Diaminorhodamine-4M (DAR-4M) was purchased from
Calbiochem. Megalomicin was a generous gift from Balbino Alarcón (Universidad
Autónoma de Madrid, Madrid, Spain).
Construction of the GFP fusion proteins, plasmids and
mutagenesis
We have described the cloning and expression of the full-length wild-type NOS2,
which possessed the initial sequence MACPWKFLFKVKSYQSD. Site-directed
mutagenesis was used to introduce the desired mutations and we created the
following constructs: wild-type, C3S, Myr, Myr/C3S, A2C (Fig. 1). Every mutant
was obtained as a full-length NOS2-GFP chimera and as a NOS2-(1-94)-GFP
chimera. The restriction sites used are described in detail elsewhere (Navarro-
Lérida et al., 2004a; Navarro-Lérida et al., 2004b). The wild-type GAP-43-GFP
and the PSD-95-GFP clones were generous gifts of Luc Berthiaume (University of
Alberta, Alberta, Canada) and David Bredt (University of California, San
Francisco, CA).
Immunoblot analysis, cellular fractionation, laser confocal
microscopy, metabolic labelling and immunoprecipitation
The cellular biology techniques described in this manuscript were performed
as described elsewhere (Navarro-Lérida et al., 2004a; Navarro-Lérida et al.,
2004b).
Fluorescence recovery after photobleaching
To study the dynamics of NOS2 and its myristoylated mutant in living cells, we
used fluorescence recovery after photobleaching (FRAP). Focusing 100% of argon
laser power (blue light of 488-nm length) on small areas of plasma membrane,
NOS2 associated in this region was photobleached irreversibly for 50 seconds.
Then, 3% of laser power was used to image the GFP at different times. The changes
in the signal intensity before photobleaching and in the subsequent time points after
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Preparation of caveolin-enriched DRMs
Our flotation experiments in the presence of Triton X-100 followed the published
protocol of Lisanti (Lisanti et al., 1999). The method is described in detail elsewhere
(Navarro-Lérida et al., 2004a; Navarro-Lérida et al., 2004b).
Recombinant expression of NOS in E. coli, purification and
NOS2 assay
The cDNA coding for NOS2 with an N-terminal deletion of the first 33 amino acids
was constructed by PCR with a NdeI site at the 5 end, subcloned in the pGEMT
vector (Promega) and sequenced. The amplified band was digested with NdeI and
XbaI, cloned in the corresponding sites of the expression vector pCWori and was
named 33-NOS2. This construction was used to routinely transform competent
BL21 cells (Novagen) where the coexpression vector for calmodulin was already
inserted. Four litres of 2YT media were used for protein expression at 22°C. The
protein was purified using two affinity columns as previously described (Rodríguez-
Crespo et al., 1996a; Rodríguez-Crespo et al., 1996b). The NOS assay has been
described elsewhere (Navarro-Lérida et al., 2004a; Navarro-Lérida et al., 2004b).
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